Inhibition by apomorphine of the metoclopramide-induced catalepsy and increase in striatal homovanillic acid content.
1 The mechanism of the cataleptic effect of metoclopramide was analyzed by using drugs which alter the activity of dopaminergic or cholinergic neurones or the content of  psi-aminobutyric acid in the central nervous system of rats. 2 The cataleptic effect of metoclopramide (20 mg/kg) was antagonized by apomorphine (10 mg/kg) and by atropine (50 mg/kg). Aminoxyacete acid (AOAA, 25-50 mg/kg) potentiated the catalepsy induced by metoclopramide (5 mg/kg). 3 Metoclopramide alone did not alter the rectal temperature of rats. It did not alter the AOAA-induced hypothermia, but it partially antagonized apomorphine-induced hypothermia. 4 Metoclopramide induced a six-fold increase in striatal homovanillic acid (HVA) concentration, but it did not change the dopamine or noradrenaline content in the brain of rats. Apomorphine decreased the striatal HVA concentration in control and in metoclopramide-treated rats. Atropine and AOAA did not alter the metoclopramide-induced increase in striatal HVA concentration. 5 The results suggest that metoclopramide produces catalepsy by blocking striatal dopamine receptors.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002375:Catalepsy / Q000139:chemically induced*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006719:Homovanillic Acid / Q000378:metabolism*; D006801:Humans; D008787:Metoclopramide / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D010648:Phenylacetates / Q000378:metabolism*; D051381:Rats; D013268:Stimulation, Chemical; D013997:Time Factors
D010648:Phenylacetates; D008787:Metoclopramide; D001058:Apomorphine; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid